Digital surgery platform developer Caresyntax announced today that it added a $30 million extension to its Series C funding round.
Boston-based Caresyntax’s $30 million extension brings its total Series C funding to $130 million, adding to the first stage announced in April 2021, according to a news release.
PFM Health Sciences led the extension, with selected investors including funds and accounts managed by BlackRock, as well as ProAssurance, Harmonix and existing investors such as the Relyens Group and IPF Partners. The overall Series C features investments from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, and Surgical.AI.
Caresyntax said the funding will be used to continue developing its digital surgery platform, which uses proprietary software and AI to analyze large volumes of real-world data in and around the operating room to offer insights for immediate use by…